Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
| Revenue (TTM) | $133.95M |
| Gross Profit (TTM) | $202.82M |
| EBITDA | $54.36M |
| Operating Margin | 36.20% |
| Return on Equity | -1279.00% |
| Return on Assets | 13.60% |
| Revenue/Share (TTM) | $3.03 |
| Book Value | $-2.33 |
| Price-to-Book | 218.61 |
| Price-to-Sales (TTM) | 2.41 |
| EV/Revenue | 2.354 |
| EV/EBITDA | 2.00 |
| Quarterly Earnings Growth (YoY) | -99.00% |
| Quarterly Revenue Growth (YoY) | 4.10% |
| Shares Outstanding | $45.16M |
| Float | $40.43M |
| % Insiders | 6.27% |
| % Institutions | 44.87% |
Volatility is currently contracting
AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, in heavily pretreated patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The results were prese.
Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives said during an investor event.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, before surgery in patients with high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. The cli.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, alone or in combination with balstilimab (BAL), Agenus' anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The.
Agenus NASDAQ: AGEN is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after ending funding for its BATTMAN study in later-line metastatic disease.
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, has been accepted for presentation at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada. The presentation will feature results from the recurre.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September. Cantor Global Healthcare Conference 2026 September 9 -11, 2026; New York, NY Fireside Chat: Tuesday, September 8, 2026 | 11:30 a.m-12:00 p.
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in a curative-intent treatment setting before surgery in high-risk, resectable microsatellite-stable (MSS) colon cancer. As previ.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AGEN and any ticker you trade — then tracks every position and per-strategy win rate.
